Advertisement
Screener

OLEMA PHARMACEUTICALS, INC. (OLMA) Graph

OLMA Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $57.78M; Operating expenses $67.18M; Net income -$63.20M.
  • 2026-03-31: Research and development $49.23M; Operating expenses $57.99M; Net income -$53.09M.
  • 2025-12-31: Research and development $43.22M*; Operating expenses $50.08M*; Net income -$46.06M*.
  • 2025-09-30: Research and development $39.95M; Operating expenses $45.88M; Net income -$42.22M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesNet income
2026-06-30$57.78M$67.18M-$63.20M
2026-03-31$49.23M$57.99M-$53.09M
2025-12-31$43.22M*$50.08M*-$46.06M*
2025-09-30$39.95M$45.88M-$42.22M
2025-06-30$43.90M$47.86M-$43.78M
2025-03-31$30.62M$34.87M-$30.39M
2024-09-30$33.23M$37.62M-$34.55M
2024-06-30$29.11M$33.53M-$30.38M
2024-03-31$29.88M$34.34M-$30.97M
2023-09-30$19.45M$23.34M-$21.50M
2023-06-30$17.99M$21.60M-$20.09M
2023-03-31$22.83M$29.60M-$28.29M
2022-09-30$17.63M$23.22M-$22.72M
2022-06-30$27.05M$33.29M-$32.86M
2022-03-31$16.01M$23.25M-$23.03M
2021-09-30$12.52M$17.76M-$17.71M
2021-06-30$11.91M$16.52M-$16.41M
2021-03-31$10.69M$15.45M-$15.34M
2020-09-30$4.67M$7.87M-$7.84M
2020-06-30$1.95M$2.49M-$2.45M
2020-03-31$795.00K$1.04M-$1.69M

Revenue and expense 6 month

Period endResearch and developmentOperating expensesNet income
2026-06-30$107.02M$125.17M-$116.29M
2025-06-30$74.53M$82.74M-$74.17M
2024-06-30$58.99M$67.87M-$61.35M
2023-06-30$40.81M$51.20M-$48.38M
2022-06-30$43.06M$56.55M-$55.89M
2021-06-30$22.60M$31.97M-$31.75M
2020-06-30$2.74M$3.53M-$4.15M

Revenue and expense 9 month

Period endResearch and developmentOperating expensesNet income
2025-09-30$114.48M$128.61M-$116.39M
2024-09-30$92.22M$105.49M-$95.91M
2023-09-30$60.27M$74.55M-$69.88M
2022-09-30$60.69M$79.77M-$78.61M
2021-09-30$35.13M$49.73M-$49.46M
2020-09-30$7.42M$11.40M-$11.99M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-12-31$157.70M$178.70M$3.00K-$162.45M
2024-12-31$124.52M$142.26M$2.00K-$129.47M
2023-12-31$86.14M$104.96M$2.00K-$96.66M
2022-12-31$82.27M$106.99M$1.00K-$104.79M
2021-12-31$51.10M$71.49M(m)-$71.10M
2020-12-31$13.70M$21.53M(m)-$22.12M
2019-12-31$3.92M$4.32M(m)-$4.32M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aclaris Therapeutics, Inc. (ACRS)United States$0.792B-9.78
Wave Life Sciences, Inc. (WVE)$0.780B-5.56
GERON CORP (GERN)United States$0.803B-12.14
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78
GYRE THERAPEUTICS, INC. (GYRE)United States$0.818B-24.71
LEXICON PHARMACEUTICALS, INC. (LXRX)United States$0.823B-17.48
Obsidian Therapeutics, Inc. (OBX)United States$0.829B
Faeth Therapeutics, Inc. (FTH)United States$0.750B
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44
Avalo Therapeutics, Inc. (AVTX)United States$0.842B-9.74